RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke

NCT ID: NCT01963832

Last Updated: 2015-01-12

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-30
• Study Completion Date: 2021-11-30

Brief Summary

Stroke patients who have little or no voluntary movement in the hand on the more affected side of their body more than one year after stroke have few treatment options. This project proposes to test the efficacy of a form of Constraint-Induced Movement therapy designed for patients with such severe impairment in conjunction with an agent, fluoxetine, which has been shown in some studies to enhance brain neuroplasticity in response to training. Constraint-Induced Movement therapy, which is abbreviated CIMT, is a form of physical rehabilitation based on basic research in neuroscience and behavioral science. If the project is successful, an efficacious, evidence-based therapy will become available to stroke patients for what is now a largely untreated condition

Conditions

Severe Stroke With Affected Arm Motor Function

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

eCMIT and Fluoxetine

expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)

Group Type: EXPERIMENTAL

Fluoxetine

Intervention Type: DRUG

eCMIT

Intervention Type: PROCEDURE

eCIMT and placebo

expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo

Group Type: EXPERIMENTAL

Fluoxetine

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Usual care and fluoxetine

Ususal physical care combined with Fluoxetine (FLX)

Group Type: EXPERIMENTAL

Fluoxetine

Intervention Type: DRUG

Usual Care

Intervention Type: PROCEDURE

Usual care and placebo

Usual physical care combined with placebo

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Usual Care

Intervention Type: PROCEDURE

Interventions

Fluoxetine

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

eCMIT

Intervention Type: PROCEDURE

Usual Care

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Motor criteria determinations will be made with the subject sitting. The more-affected forearm will be resting on a supporting surface (e.g., arm of a chair) to allow for maximum wrist flexion with gravity.
• The minimum motor criterion (MMC) for inclusion in Grade 5 (severe impairment) will be ability to:

• initiate extension against gravity at the wrist or at least one digit,
• initiate extension and flexion at the elbow,
• actively move the shoulder ≥ 30° in flexion, abduction, or scaption
• The MMC for inclusion in Grade 4 (moderately severe impairment) will be ability to actively:

• extend at least two fingers more than 0° but less than < 10°,
• extend or abduct thumb ≥ 10°
• extend wrist ≥ 10° from a fully flexed starting position,
• extend elbow ≥ 20° from a 90° flexed starting position,
• flex and abduct shoulder > 45°.
• Stroke patients who can extend at least two fingers ≥ 10° at the metacarpophalangeal (MCP) joint and either the proximal or distal interphalangeal (PIP or DIP) joint will be excluded.

• must score ≤ 4 on the Modified Ashworth Scale (23)116 for all more-affected arm joints
• meet the following passive range of movement criteria:

• ≥ 90° shoulder flexion,
• ≥ 90° shoulder abduction,
• ≥ 45° shoulder external rotation,
• ≤ 30° short of normal elbow extension, forearm supination to at least neutral,
• forearm pronation 45° or more from neutral,
• ≤ 35° short of normal wrist extension,
• ≤ 35° short of normal MCP extension on all the digits.

Exclusion Criteria

• Less than 1 year post-stroke.
• Frailty or insufficient stamina to carry out the requirements of the therapy (based on clinical judgment).
• Ferrous metal in body or medical complications or psychological problems that would prohibit receiving an MRI.
• Positive pregnancy test for women of child-bearing age since 3T MRI is contraindicated for pregnant women.
• Other neurological or musculoskeletal conditions affecting UE function.
• Medication will not be exclusionary except in the following cases: a. participation in any experimental drug study, b. Botox injections to the more-affected UE < 3 months prior to enrollment, c. Baclofen or Dantrium taken orally at the time of study, d. fluoxetine or other antidepressant with SSRI-like properties taken < 3 months prior to enrollment, e. any agents that would contraindicate concurrent fluoxetine. If subjects are on other medications, the medications will be recorded and the possible effect on treatment outcome will be analyzed separately.
• Moderate or greater depressive symptoms as indicated by a score > 30/63 on the Beck Depression Inventory (24,25).117, 118
• Concurrent participation in any formal physical rehabilitation program or clinical trial.
• Excessive pain in any joint of the more-affected arm that could limit ability to cooperate with the intervention (based on clinical judgment).
• Serious cognitive deficits manifested by a Folstein Mini-Mental State Examination (MMSE) score ≤ 24 (26).119
• Inadequate ability to follow test instructions as indicated by a Token Test of the Multilingual Aphasia Examination score ≤ 36 (27).120
• Serious, uncontrolled medical problems as judged by the Medical Director (e.g., severe rheumatoid arthritis, serious joint deformity of arthritic origin, symptomatic cancer or renal disease, any end-stage pulmonary or cardiovascular disease, senility or a deteriorated condition due to age, uncontrolled epilepsy).
• Motor problems that are not primarily unilateral.
• Poor motivation to participate in the study (if a person is only marginally interested, he/she is a bad risk as a subject).
• Less than 40 years old.
• Previous CIMT.

• Minimum Eligible Age: 40 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Countries

United States

Other Identifiers

F130410007

Identifier Type: -

Identifier Source: org_study_id